Immunomodulation in inflammatory neuropathies: rationale and safety

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Inflammatory neuropathies are immune-mediated peripheral nerve disorders.
• Prevalence is higher than previously thought.
• Established treatments include IVIg, corticosteroids, and plasma exchange.

Purpose of the Study:

• To review and discuss immunomodulatory and immunosuppressive agents for inflammatory neuropathies.
• Analyze the rationale and benefit-to-risk ratio of these treatments.
• Highlight evidence for refractory cases and reducing established therapy burdens.

Main Methods:

• Review of published evidence on immunosuppressive and immunomodulatory drugs.
• Analysis of drug efficacy in refractory inflammatory neuropathies.
• Evaluation of safety profiles and adverse effects.

Main Results:

• Established treatments are not effective for all patients.
• Immunosuppressants (conventional and novel like Rituximab) are used for refractory cases.
• Immunomodulatory drugs (e.g., interferon beta) and newer agents (e.g., Fingolimod) are under investigation.

Conclusions:

• Immunosuppressive and immunomodulatory agents offer treatment options for refractory inflammatory neuropathies.
• Careful consideration of the benefit-to-risk ratio is crucial.
• Ongoing research is exploring newer therapeutic agents.